Methadone for Chronic Pain: A Review of Pharmacology, Efficacy, and Safety Concerns

HPR

Health Psychology Research

TBA2420-8124

Health Psychology Research

10.52965/001c.129552

General

Methadone for Chronic Pain: A Review of Pharmacology, Efficacy, and Safety Concernshttps://healthpr.org/journal/HPR/13/1/10.52965/001c.129552BrownPatrick,RyderAlexa,ValentiKayla,PhungKatie,HasoonJamal

2025

131

2025-03-02

Purpose of Review Methadone is a synthetic opioid extensively used in opioid use disorder management but is gaining recognition for its unique pharmacological properties that make it a viable alternative for chronic pain management. This review aims to explore methadone’s pharmacokinetics, pharmacodynamics, efficacy, and safety profile to assess its potential role in managing chronic pain conditions.   Recent Findings Methadone’s dual action as a mu-opioid receptor agonist and NMDA receptor antagonist positions it as an effective option for managing both nociceptive and neuropathic pain. It has shown promising results in cancer pain management, refractory pain, and opioid rotation strategies. Despite its therapeutic advantages, concerns regarding its narrow therapeutic window, variable pharmacokinetics, QT interval prolongation, and risk of respiratory depression highlight the need for careful patient selection and monitoring. New evidence also sheds light on its affordability and efficacy in low-resource settings, as well as its controversial role in mitigating opioid-induced hyperalgesia.   Summary Methadone offers a unique therapeutic option in chronic pain management due to its multifaceted pharmacological properties. While it provides significant benefits for patients with complex pain syndromes, clinicians must exercise caution due to its safety concerns and variability in individual metabolism. A personalized approach, combined with rigorous monitoring, is essential to optimize its benefits while minimizing risks. Further research is needed to better define its role in chronic pain treatment and address unresolved safety concerns.

1.Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: A mechanistic and clinical review. British Journal of Anaesthesia. 2020;124(1):44-62. doi:10.1016/j.bja.2019.08.010 Google Scholar 2.Hanna V, Senderovich H. Methadone in pain management: A systematic review. The Journal of Pain. 2021;22(3):233-245. doi:10.1016/j.jpain.2020.04.004 Google Scholar 3.Dydyk A, Conermann T. Chronic Diseases: An Encyclopedia of Causes, Effects, and Treatments. In: Chronic Pain. Vol 2. ; 2024:599-601. Google Scholar 4.de Barros GAM, Baradelli R, Rodrigues DG, et al. Use of methadone as an alternative to morphine for chronic pain management: A noninferiority retrospective observational study. Pain Reports. 2021;6(4):e979. doi:10.1097/PR9.0000000000000979 Google ScholarPubMed CentralPubMed 5.Heung Y, Reddy A. How to use methadone in an era of an opioid epidemic. Current Treatment Options in Oncology. 2020;21:1-10. doi:10.1007/s11864-020-0724-4 Google Scholar 6.Kreutzwiser D, Tawfic QA. Methadone for pain management: A pharmacotherapeutic review. CNS Drugs. 2020;34(8):827-839. doi:10.1007/s40263-020-00743-3 Google Scholar 7.Drug Fact Sheet: Methadone. Department of Justice/ Drug Enforcement Administration. https://www.dea.gov/sites/default/files/2020-06/Methadone-2020_0.pdf 8.Lai G, Aroke EN, Zhang SJ. Rediscovery of methadone to improve outcomes in pain management. Journal of PeriAnesthesia Nursing. 2022;37(4):425-434. doi:10.1016/j.jopan.2021.08.011 Google Scholar 9.Ferrari A, Coccia CPR, Bertolini A, Sternieri E. Methadone—Metabolism, pharmacokinetics and interactions. Pharmacological Research. 2004;50(6):551-559. doi:10.1016/j.phrs.2004.05.002 Google Scholar 10.Koehl A, Hu H, Maeda S, et al. Structure of the µ-opioid receptor–Gi protein complex. Nature. 2018;558(7711):547-552. Google Scholar 11.Durrani M, Bansal K. Methadone. In: StatPearls [Internet]. StatPearls Publishing; 2024. Google Scholar 12.Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: Link to clinical reports of serotonin syndrome. British Journal of Pharmacology. 2018;175(3):532-543. doi:10.1111/bph.14105 Google ScholarPubMed CentralPubMed 13.Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: Morphine, methadone and naloxone. Clinical Pharmacokinetics. 1976;1:219-188. doi:10.2165/00003088-197601030-00004 Google Scholar 14.Tran THH. Methadone Patients in Vietnam: Substance Use Patterns, Reasons for Entering Treatment, and Methadone-Related Attitudes. Published online 2023. Google Scholar 15.Mercadante S, Bruera E. Methadone as a first-line opioid in cancer pain management: A systematic review. Journal of Pain and Symptom Management. 2018;55(3):998-1003. doi:10.1016/j.jpainsymman.2017.10.017 Google Scholar 16.Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database of Systematic Reviews. 2017;(2). doi:10.1002/14651858.CD003971.pub4 Google ScholarPubMed CentralPubMed 17.Ding H, Song Y, Xin W, et al. Methadone Switching for Refractory Cancer Pain. BMC Palliative Care. 2022;21(1):191-197. doi:10.1186/s12904-022-01076-2 Google Scholar 18.GoodRx. GoodRx Prescription Prices. GoodRx. Accessed December 2, 2024. https://www.goodrx.com 19.Gagnon B, Almahrezi A, Schreier G. Methadone in the Treatment of Neuropathic Pain. Pain Research & Management. 2003;8(3):149-154. doi:10.1155/2003/236718 Google Scholar 20.Altier N, Dion D, Boulanger A, Choinière M. Management of Chronic Neuropathic Pain with Methadone: A Review of 13 Cases. The Clinical Journal of Pain. 2005;21(4):364-369. doi:10.1097/01.ajp.0000125247.95213.53 Google Scholar 21.Tompkins DA, Campbell CM. Opioid-Induced Hyperalgesia: Clinically Relevant or Extraneous Research Phenomenon? Current Pain and Headache Reports. 2011;15(2):129-136. doi:10.1007/s11916-010-0171-1 Google Scholar 22.Vorobeychik Y, Chen L, Bush MC, Mao J. Improved Opioid Analgesic Effect Following Opioid Dose Reduction. Pain Medicine (Malden, Mass). 2008;9(6):724-727. doi:10.1111/j.1526-4637.2008.00501.x Google Scholar 23.Chu LF, Angst MS, Clark D. Opioid-Induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations. The Clinical Journal of Pain. 2008;24(6):479-496. doi:10.1097/AJP.0b013e31816b2f43 Google Scholar 24.Yi P, Pryzbylkowski P. Opioid Induced Hyperalgesia. Pain Medicine. Published online 2015. doi:10.1111/pme.12914 Google Scholar 25.Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the Treatment of Addiction: Methadone. Journal of Addictive Diseases. 2010;29(2):200-216. doi:10.1080/10550881003684798 Google Scholar 26.Dole VP, Kreek MJ. Methadone Plasma Level: Sustained by a Reservoir of Drug in Tissue. Proceedings of the National Academy of Sciences - PNAS. 1973;70(1):10-10. doi:10.1073/pnas.70.1.10 Google Scholar 27.Toombs JD, Kral LA. Methadone Treatment for Pain States. American Family Physician. 2005;71(7):1353. Google Scholar 28.Repple J, Haessner S, Johnen A, et al. Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments. BMC Neurology. 2021;21:1-6. doi:10.1186/s12883-021-02108-9 Google ScholarPubMed CentralPubMed 29.Miano TA, Wang L, Leonard CE, et al. Identifying clinically relevant drug–drug interactions with methadone and buprenorphine: A translational approach to signal detection. Clinical Pharmacology & Therapeutics. 2022;112(5):1120-1129. doi:10.1002/cpt.2717 Google ScholarPubMed CentralPubMed 30.Centers for Disease Control and Prevention (CDC). Vital signs: Risk for overdose from methadone used for pain relief-United States, 1999-2010. MMWR: Morbidity & Mortality Weekly Report. 2012;61(26). Google Scholar 31.Faul M. Methadone prescribing and overdose and the association with Medicaid preferred drug list policies—United States, 2007–2014. MMWR Morbidity and Mortality Weekly Report. 2017;66. doi:10.15585/mmwr.mm6612a2 Google ScholarPubMed CentralPubMed 32.Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. The Journal of Pain. 2014;15(4):321-337. doi:10.1016/j.jpain.2014.01.494 Google Scholar 33.Rajan J, Scott-Warren J. The clinical use of methadone in cancer and chronic pain medicine. BJA Education. 2016;16(3):102-106. doi:10.1093/bjaceaccp/mkv023 Google Scholar 34.Walsh SL, Strain EC. Pharmacology of methadone. In: The Treatment of Opioid Dependence. ; 2006:59-76. Google Scholar 35.Nosyk B, Min JE, Homayra F, et al. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA. 2024;332(21):1822-1831. doi:10.1001/jama.2024.16954 Google Scholar 36.Fipps DC, Oesterle TS, Kolla BP. Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder. Seminars in neurology. 2024;44(4):441-451. doi:10.1055/s-0044-1787571 Google Scholar 37.Vu PD, Bansal V, Chitneni A, et al. Buprenorphine for Chronic Pain Management: a Narrative Review. Current pain and headache reports. 2023;27(12):811-820. doi:10.1007/s11916-023-01185-4 Google Scholar 38.Dalal S, Chitneni A, Berger AA, et al. Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health psychology research. 2021;9(1):27241. doi:10.52965/001c.27241 Google Scholar 39.Poliwoda S, Noor N, Jenkins JS, et al. Buprenorphine and its formulations: a comprehensive review. Health psychology research. 2022;10(3):37517. doi:10.52965/001c.37517 Google Scholar